SCHEMBL23782822

SCHEMBL23782822

Brc1ccc2c(c1)c(CC1CC1)nn2C1CCCCO1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
MAPK1 P28482 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CNR2 P34972 3/20 0.32
CNR1 P21554 1/20 0.32
CYP4F2 P78329 4/20 0.32
CYP4A11 Q02928 4/20 0.32
ALOX15 P16050 1/20 0.32
CDK1 P06493 1/20 0.32
FLT3 P36888 2/20 0.31
RET P07949 1/20 0.31
RAB9A P51151 1/20 0.31
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23219108 0.87 RXRA (0.39) MAPTRXRARXRBRXRGMAPK1
SCHEMBL23782865 0.86 RXRA (0.36) MAPTRXRARXRBRXRGALDH1A1
SCHEMBL30182911 0.83 MAPT (0.38) MAPTRXRARXRBRXRGMAPK1
SCHEMBL15744178 0.81 CYP4F2 (0.39) MAPTRXRARXRBRXRGMAPK1
SCHEMBL767404 0.81 CYP4F2 (0.39) MAPTRXRARXRBRXRGMAPK1
SCHEMBL18281904 0.81 GAA (0.41) MAPTRXRARXRBRXRGMAPK1
SCHEMBL24268653 0.81 MAPT (0.37) MAPTRXRARXRBRXRGMAPK1
SCHEMBL9904367 0.81 MAPT (0.37) MAPTRXRARXRBRXRGMAPK1
SCHEMBL30615352 0.81 MAPT (0.37) MAPTRXRARXRBRXRGMAPK1
SCHEMBL660435 0.79 ALDH1A1 (0.36) MAPTRXRARXRBRXRGMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 US disclosed
WO-2021178780-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2021-09-10 WO disclosed
WO-2021178780-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2021-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS LRRK2, PARK7, GDI2 MAPT 66/4885RXRA 4749/4885RXRB 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.